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Limited information exists about the prevalence, management, and outcomes of intermediate-high risk patients with acute pulmonary embolism (PE). In a prospective cohort study,
we evaluated consecutive patients with intermediate-high risk PE at a large, tertiary,
academic medical center between January 1, 2015 and March 31, 2019. Adjudicated
outcomes included PE-related mortality and a complicated course through 30 days after
initiation of PE treatment. Repeat systolic blood pressure (SBP), heart rate (HR), brain
natriuretic peptide (BNP), and cardiac troponin I (cTnI) measurements, and echocardiography were performed within 48 hours after diagnosis. Among 1,015 normotensive
patients with acute PE, 97 (9.6%) had intermediate-high risk PE. A 30-day complicated
course and 30-day PE-related mortality occurred in 23 (24%) and 7 patients (7.2%) with
intermediate-high risk PE. Seventeen (18%) intermediate-high risk patients received
reperfusion therapy. Within 48 hours after initiation of anticoagulation, normalization of
SBP, HR, cTnI, BNP, and echocardiography occurred in 82, 86, 78, 72, and 33% of survivors
with intermediate-high risk PE who did not receive immediate thrombolysis. A complicated
course between day 2 and day 30 after PE diagnosis for the patients who normalized SBP,
HR, cTnI, BNP, and echocardiography measured at 48 hours occurred in 2.9, 1.4, 4.5, 3.3,
and 14.3%, respectively. Intermediate-high risk PE occurs in approximately one-tenth of
patients with acute symptomatic PE, and is associated with high morbidity and mortality.
Normalization of HR 48 hours after diagnosis might identify a group of patients with a very
low risk of deterioration during the ﬁrst month of follow-up.
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Introduction
Hemodynamically unstable acute pulmonary embolism (PE)
is a cardiovascular emergency, associated with high risk of
death from worsening right ventricle (RV) failure and cardiogenic/obstructive shock, with an in-hospital mortality
rate of > 15%.1–3 For normotensive patients diagnosed with
PE, risk stratiﬁcation should aim to identify the group of
patients deemed as having a high risk for a PE-related
complicated course (intermediate-high risk PE) that might
beneﬁt from intensive monitoring or escalation of therapy.4
Prior investigations from existing PE registries have provided some important insights into the use of prognostic
tools to identify patients with intermediate-high risk PE.5,6
According to the European Society of Cardiology (ESC) guidelines, normotensive PE patients with a positive prognostic
score (i.e., Pulmonary Embolism Severity Index [PESI], simpliﬁed PESI [sPESI]), and evidence of RV dysfunction by
elevated cardiac biomarkers (i.e., cardiac troponin test) and
imaging should be classiﬁed into an intermediate-high risk
category.4 However, studies have shown conﬂicting data
regarding the prognostic signiﬁcance of intermediate-high
risk PE.7,8 While one study found the proportion of complications for patients in the intermediate-high risk group to be
signiﬁcantly higher than in the intermediate-low risk group
(17.5 vs. 10%),7 another study did not conﬁrm these ﬁndings.8 There remains limited contemporary information
about the epidemiology, management, and outcomes of
patients with intermediate-high risk PE. Further, there is
uncertainty about the subgroup of patients with intermediate-high risk PE who are more likely to deteriorate, and hence
may beneﬁt from reperfusion.
Accordingly, we conducted a prospective cohort study to
determine the prevalence, treatment patterns, and associated outcomes for patients with intermediate-high risk PE in
routine clinical practice, and to explore the markers of early
response to anticoagulant therapy.

Methods
Study Design
Consecutive normotensive patients with a diagnosis of acute
PE between January 1, 2015 and March 31, 2019 were
approached for enrollment in a prospective study. All
patients provided informed consent for their participation
in the study in accordance with the requirements of the
ethics committee of the hospital, and the human subjects
committee approved this study.

Patients, Setting, and Eligibility Criteria
Patients were recruited from the emergency department of
Ramón y Cajal Hospital, Madrid, Spain. Eligibility for this
study required that patients have acute symptomatic PE
conﬁrmed by either a contrast-enhanced PE protocol helical
chest computed tomography (CT),9 a high probability ventilation–perfusion scan result according to the criteria of the
Prospective Investigation of Pulmonary Embolism Diagnosis,10 or a lower limb venous compression ultrasonography
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positive for a proximal deep vein thrombosis in patients with
inconclusive ventilation–perfusion scans.11

Deﬁnition of Intermediate-High Risk PE
We deﬁned intermediate-high risk PE as the presence of
hemodynamic stability (systolic blood pressure [SBP] 
90 mm Hg), a positive sPESI, and concomitant echocardiographic RV dysfunction, and positive cardiac troponin.4

Calculation of the sPESI
Using the baseline data collected at the time of PE diagnosis,
investigators prospectively determined the sPESI.12 The sPESI
categorized patients with none of the variables present as
negative, and those with at least one factor present as positive.

Transthoracic Echocardiography
The study required that patients undergo transthoracic
echocardiography within 12 hours after diagnosis of PE.
Trained and certiﬁed local cardiologists interpreted
each echocardiogram. The study deﬁned echocardiographic RV dysfunction as the presence of at least two
of the following: dilatation of the RV (end-diastolic diameter > 30 mm from the parasternal view or the RV appearing larger than the left ventricle from the subcostal or
apical view), hypokinesis of the RV free wall (any view),
and estimated systolic pulmonary artery pressure over
30 mm Hg.13,14

Cardiac Biomarker Determinations
The Hospital Universitario Ramon y Cajal-IRYCIS Biobank
processed the biological samples. The laboratory personnel,
blinded to the patients’ baseline characteristics and clinical
outcome, measured cardiac troponin I (cTnI) levels quantitatively by using a microparticle enzyme immunoassay
(MEIA) (Abbot, United States). The study deﬁned cTnI concentrations of > 0.05 ng/mL as indicative of myocardial injury (cTnI positive).13,15 Brain natriuretic peptide (BNP) levels
were measured by the MEIA system immunoassay in an
Architect i2000 analyzer (Abbott). The study protocol deﬁned BNP concentrations of >100 pg/mL as indicative of
cardiac myocyte stretch (BNP positive).16

Study Endpoints and Outcome Measures
The study used PE-related mortality and a “complicated
course” as the study endpoints. Investigators determined
survival status by conducting patient or proxy interviews,
and/or hospital chart review. Fatal PE was deﬁned as death
from PE conﬁrmed by autopsy or death following a clinically
severe PE, either initially or shortly after an objectively
conﬁrmed recurrent event, in the absence of any alternative
diagnosis. A “complicated course” was deﬁned as a composite of PE-related death, hemodynamic collapse (deﬁned
as need for cardiopulmonary resuscitation, SBP < 90 mm Hg
for at least 15 minutes, need for vasopressor administration,
or need for reperfusion with thrombolytic therapy or
surgery), or recurrent PE within the 30 days of follow-up.
Two investigators (R.M. and F.L.) adjudicated all serious
adverse events.
TH Open
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We deﬁned major bleeding episodes as those that required a transfusion of at least 2 units of blood, were
retroperitoneal, spinal or intracranial, or were fatal.

Treatment and Follow-Up
Between January 1, 2015 and January 1, 2018, clinicians
managed patients according to their own practice (i.e., no
standardization of treatment). After January 1, 2018, a
Pulmonary Embolism Response Team coordinated clinical
care of patients with high- and intermediate-high risk PE.
The study recorded information related to patient outcomes
through 30 days after the diagnosis of the acute PE.

Statistical Analyses
The study reported categorical data as proportions and
continuous data as mean  standard deviation or median
(ﬁrst–third interquartile range). We used unpaired twotailed t-tests or the Mann–Whitney U test (for those variables
found not to follow a normal distribution) for comparisons in
the distributions of continuous variables between intermediate-high risk versus low- and intermediate-low risk PE
patients, and chi-squared or Fisher’s exact tests to compare
the categorical data between the two groups. We also used
these tests to explore differences between the patients with
intermediate-high risk PE who did and did not receive any
kind of reperfusion therapies (i.e., systemic thrombolysis,
local thrombolysis, percutaneous procedures, and surgical
embolectomy).
For survivors who did not receive immediate (i.e., at the
time of PE diagnosis) thrombolysis, repeat SBP, heart rate
(HR), cTnI, and BNP measurements, and echocardiography
were performed within 48 hours after initiation of anticoagulation. Assessment of vital signs was done by the
study cardiologists just before the repeat echocardiogram.
Normalization of prognostic tests was deﬁned as an increase in SBP > 100 mm Hg, a decrease in HR < 100 beats
per minute, a decrease in cTnI levels to  0.05 ng/mL, a
decrease in BNP levels to  100 pg/mL, and absence of
echocardiographic RV dilation and dysfunction. For each
test risk subgroup (i.e., negative vs. positive), the propor-

Fig. 1 Patient ﬂow diagram. PE, pulmonary embolism.
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tion of patients with 30-day adverse outcomes was determined. To assess the test and performance characteristics
of each test negative versus positive categories, we estimated sensitivity, speciﬁcity, and positive and negative
predictive values.
Analyses were performed using SPSS, version 23.0 for the
personal computer (SPSS Inc., Chicago, Illinois, United
States). All hypothesis tests were two-sided, with a signiﬁcance level of 0.05.

Results
We enrolled 1,015 normotensive patients with acute PE (486
men and 529 women) from January 1, 2015 to March 31,
2019 (►Fig. 1). Overall, 97 patients (9.6%; 95% conﬁdence
interval [CI], 7.8–11.5%) had intermediate-high risk, 571
(56%) patients had intermediate-low risk, and 347 (34%)
had low-risk PE. Patients with intermediate-high risk PE
differed signiﬁcantly from those with low- and intermediate-low risk PE in preexisting medical conditions, and in
relevant clinical, physiologic, and laboratory parameters. As
expected, patients with intermediate-high risk PE were older
and had more comorbid diseases (immobility, high-risk
sPESI), and signs of clinical severity (tachycardia, hypoxemia,
and hypotension), compared with those with low- or intermediate-low risk PE (►Table 1).

Treatment Patterns
Seventeen (18%; 95% CI, 11–27%) intermediate-high risk
patients received reperfusion therapy (6 patients received
immediate thrombolysis at the time of PE diagnosis, and 11
patients after clinical deterioration). No patient received
surgical or catheter embolectomy. Patients who received
reperfusion were younger than patients who did not receive
reperfusion (57  20 vs. 73  14 years), and more frequently
presented with chest pain, tachycardia, and hypotension,
compared with intermediate-high risk patients who did not
receive reperfusion (►Table 2). Interestingly, the two treatment groups had similar proportions of male gender, history
of heart failure, chronic obstructive pulmonary disease
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Table 1 Patient characteristics (n ¼ 1,015)
Intermediate-high risk PE
N ¼ 97

Low- or intermediate-low risk PE
N ¼ 918

p-Value

Clinical characteristics,
Age, y (mean  SD)

70.4  16.2

66.8  16.3

0.04

Age > 80 y

28 (30)

166 (18)

0.01

Male gender

43 (44)

443 (48)

0.52

Cancera

7 (7.2)

108 (12)

0.24

Recent surgeryb

7 (7.2)

102 (11)

0.24

History of VTE

8 (8.2)

180 (20)

< 0.01

22 (37)

211 (23)

< 0.01

Chronic lung disease

10 (11)

93 (11)

1.00

Chronic heart disease

5 (5.2)

39 (4.2)

0.60

Risk factors for VTE,

Immobilization

c

Comorbid diseases

Clinical symptoms and signs at presentation
Syncope

29 (33)

138 (15)

< 0.001

Chest pain

43 (36)

413 (45)

0.11

Dyspnea

76 (85)

771 (84)

1.00

Heart rate  110/min

42 (43)

205 (22)

< 0.001

Arterial oxyhemoglobin
saturation (SaO2) < 90%

57 (59)

147 (26)

< 0.001

SBP < 100 mm Hg

8 (8.2)

38 (4.1)

0.07

sPESI

12

Low-risk

0 (0)

347 (38)

<0.001

High-risk

97 (100)

571 (62)

< 0.001

Echocardiography and cardiac biomarkers, n (%)
RV dysfunction

97 (100)

29/24212

<0.001

cTnI > 0 ng/mL

97 (100)

115/56420

<0.001

Abbreviations: cTnI, cardiac troponin I; PE, pulmonary embolism; RV, right ventricle; SBP, systolic blood pressure; SD, standard deviation; sPESI,
simpliﬁed Pulmonary Embolism Severity Index; VTE, venous thromboembolism.
a
Active or under treatment in the last year.
b
In the previous month.
c
Immobilized patients deﬁned as nonsurgical patients with limited mobility (i.e., total bed rest with bathroom privileges) for  4 days in the month
prior to PE diagnosis.

(COPD), cancer, recent surgery, history of venous thromboembolism, and immobilization.

Outcomes
Outcomes data were available for all patients through the 30day study follow-up. The 30-day all-cause mortality rates were
10% (95% CI, 5.1–18%) in patients with intermediate-high
versus 4.0% (95% CI, 2.9–5.6%) in those with low- and intermediate-low risk PE. In the intermediate-high risk group, most
deaths (7 of 10 deaths; 70%; 95% CI, 35–93%) were attributable
to PE, while 3 patients (3.1%; 95% CI, 0.6–8.8%) died from other
causes (cancer 2, and COPD 1). Twenty-three of 97 intermediate-high risk PE patients (24%; 95% CI, 16–33%) had a complicated course. In addition to the 7 PE-related deaths,
complicated course was due to nonfatal hemodynamic col-

lapse deterioration in 16 patients (►Supplementary Table S1).
Two of 97 patients (2.1%; 95% CI, 0.3–7.3%) had recurrent
symptomatic PE (both fatal), and 4 patients (4.1%; 95% CI, 1.1–
10%) suffered a major bleeding episode (retroperitoneal 2,
intracranial 1, and need for transfusion 1).
In the subgroup of patients with intermediate-high risk
PE, PE-related mortality within 30 day of PE diagnosis
occurred in 4 patients (3.2%; 95% CI, 0.9–8.1%) who received
delayed reperfusion (i.e., after clinical deterioration), and in 3
patients (3.8%; 95% CI, 0.8–10.6%) who did not receive
reperfusion. Of the patients who received thrombolysis,
5.9% (1 of 17 patients) had recurrent PE during the 30-day
study follow-up period. Of those who did not receive thrombolysis, 1.3% (1 of 80 patients) recurred during follow-up. Of
the patients who received thrombolysis, 12% (2 of 17
TH Open
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Table 2 Clinical characteristics of patients with intermediate-high risk PE (n ¼ 97) who did or did not receive thrombolysis
Received thrombolysis
N ¼ 17

Did not receive thrombolysis
N ¼ 80

p-Value

Clinical characteristics,
Age, y (mean  SD)

56.6  20.3

73.3  13.7

< 0.001

Age > 80 y

0 (0)

28 (35)

< 0.01

Male gender

8 (47)

35 (44)

1.00

Cancera

1 (5.9)

6 (7.5)

1.00

Recent surgeryb

1 (5.9)

6 (7.5)

1.00

History of VTE

2 (12)

6 (7.5)

0.63

3 (18)

19 (24)

0.75

Chronic lung disease

0 (0)

10 (13)

0.20

Chronic heart disease

0 (0)

5 (6.3)

0.58

Risk factors for VTE,

Immobilization

c

Comorbid diseases

Clinical symptoms and signs at presentation
Syncope

4 (24)

25 (31)

0.77

Chest pain

12 (71)

31 (39)

0.03

Dyspnea

13 (76)

63 (79)

1.00

Heart rate  110/min

13 (76)

29 (36)

0.02

Arterial oxyhemoglobin
saturation (SaO2) < 90%

7 (41)

50 (63)

0.17

SBP < 100 mm Hg

5 (29)

3 (3.8)

< 0.01

Abbreviations: PE, pulmonary embolism; SBP, systolic blood pressure; SD, standard deviation; VTE, venous thromboembolism.
a
Active or under treatment in the last year.
b
In the previous month.
c
Immobilized patients deﬁned as nonsurgical patients with limited mobility (i.e., total bed rest with bathroom privileges) for  4 days in the month
prior to PE diagnosis.

patients) bled during the 30-day study follow-up period. Of
those who did not receive thrombolysis, 2.5% (2 of 80
patients) bled during follow-up.

Response to Anticoagulation
Within 48 hours after initiation of anticoagulation, repeat
SBP, HR, cTnI, and BNP measurements, and echocardiography
were obtained in 85 survivors who did not receive immediate thrombolysis. Of these, 11 (13%; 95% CI, 6.6–22%) experienced a complicated course and 8 (9.4%; 95% CI, 4.2–18%)
died between day 2 and day 30 after PE diagnosis. Overall, 5
patients (5.9%) died from deﬁnite or possible PE, 1 (1.2%)
from COPD, and 2 (2.4%) from cancer. One patient had an
episode of (fatal) recurrent PE, and 2 patients had an episode
of nonfatal major bleeding. Normalization of SBP, HR, cTnI,
BNP, and echocardiography occurred in 82, 86, 78, 72, and
33%, respectively (►Table 3).
For the patients who normalized SBP, HR, cTnI, BNP, and
echocardiography measured at 48 hours, a complicated
course occurred in 2.9, 1.4, 4.5, 3.3, and 14.3%, respectively
(►Table 3). The sensitivity, speciﬁcity, and predictive values
for the tests performed at 48 hours for predicting 30-day
adverse events are listed in ►Table 3.
TH Open
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Discussion
In this prospective cohort study, intermediate-high risk PE
occurred in 10% of normotensive patients with acute symptomatic PE, with markedly worse outcomes compared with
those with low- or intermediate-low risk PE. During the ﬁrst
30 days of follow-up, a complicated course occurred in onefourth of the patients, and 30-day PE-related mortality rate
was approximately 7%. Only one-ﬁfth of the patients with
intermediate-high risk PE received thrombolytic therapy,
most of them after clinical deterioration. Normalization of
clinical markers, including HR within 48 hours of PE diagnosis, identiﬁed patients with an uncomplicated course during
the ﬁrst month of anticoagulant therapy.
Identiﬁcation of intermediate-high risk PE has evolved
over time. Studies of patients with normotensive PE found
that those with echocardiographic RV dysfunction and myocardial injury had a greater risk of short-term death compared with patients with either echocardiographic RV
dysfunction or elevated troponin levels (or none).17,18
Accordingly, the ESC guidelines deﬁned intermediate-high
risk patients with acute symptomatic PE as those who are
hemodynamically stable, and have myocardial injury and
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Table 3 Characteristics of tests performed 48 hours after PE diagnosis for predicting 30-day adverse events
Systolic blood
pressure
normalization

Heart rate
normalization

Cardiac
troponin I
normalization

Brain natriuretic
peptide
normalization

Echocardiography
normalization

82
(73–90)

86
(77–92)

78
(67–86)

72
(61–81)

33
(23–44)

Complicated course

82
(48–97)

91
(57–100)

73
(39–93)

82
(48–97)

64
(32–88)

All-cause mortality

75
(36–96)

100

63
(26–90)

75
(36–96)

75
(36–96)

PE-related mortality

60
(17–93)

100

80
(30–99)

80
(30–99)

100

Complicated course

92
(83–97)

97
(90–100)

85
(75–92)

80
(68–88)

32
(22–44)

All-cause mortality

88
(78–94)

95
(87–98)

82
(71–89)

77
(65–85)

34
(24–46)

PE-related mortality

85
(75–92)

91
(82–96)

81
(71–89)

75
(64–84)

35
(25–47)

Complicated course

60
(33–83)

83
(51–97)

42
(21–66)

38
(20–59)

12
85.5–24)

All-cause mortality

40
(17–67)

67
(35–89)

26
(10–51)

25
(11–47)

11
(4.4–22)

PE-related mortality

20
(5.3–49)

42
(17–71)

21
(7.0–46)

17
(5.5–38)

8.8
(3.3–20)

Complicated course

97
(89–100)

99
(92–100)

95
(86–99)

97
(88–99)

86
(66–95)

All-cause mortality

97
(89–100)

100

95
(86–99)

97
(88–99)

93
(75–99)

PE-related mortality

97
(89–100)

100

98
(91–100)

98
(90–100)

100

Complicated course

10
(4.5–23)

34
(8.5–134)

4.9
(2.5–9.4)

4.0
(2.4–6.9)

0.9
(0.6–1.5)

All-cause mortality

6.4
(3.1–13)

19
(7.4–50)

3.4
(1.7–7.0)

3.2
(1.8–5.7)

1.1
(0.7–1.7)

PE-related mortality

4.0
(1.7–9.7)

11
(5.6–23)

4.3
(2.3–8.0)

3.2
(1.8–5.7)

1.5
(1.3–1.8)

Complicated course

0.2
(0.1–0.7)

0.1
(0.0–0.6)

0.3
(0.1–0.8)

0.2
(0.1–0.8)

1.1
(0.5–2.6)

All-cause mortality

0.3
(0.1–0.9)

0

0.5
(0.2–1.1)

0.3
(0.1–1.1)

0.7
(0.2–2.6)

PE-related mortality

0.5
(0.2–1.4)

0

0.3
(0.0–1.4)

0.3
(0.1–1.6)

0

Measurement
normalization,
% (95% CI)
Sensitivity,
% (95% CI)

Speciﬁcity,
% (95% CI)

Positive predictive
value,
% (95% CI)

Negative
predictive value, %
(95% CI)

Positive
likelihood ratio
(95% CI)

Negative
likelihood ratio
(95% CI)

Abbreviations: CI, conﬁdence interval; PE, pulmonary embolism.

RV dysfunction.4 More recent observational studies have
suggested an incremental prognostic value of the association
of markers of RV dysfunction and injury with clinical variables.6,19 The prevalence of intermediate-high risk in the
study cohort (10%) was lower than in a previous study in
which the prevalence was 30%.8 This discrepancy may be
explained at least in part because the present study used the
combination of a positive sPESI with echocardiographic RV
dysfunction and myocardial injury for identifying the moresevere intermediate-risk patients with acute PE, as recommended by the 2014 and 2019 ESC guidelines.4,20
The Pulmonary Embolism Thrombolysis (PEITHO) trial
was a randomized, double-blind trial that assessed the
efﬁcacy and safety of tenecteplase in normotensive patients

with RV dysfunction/enlargement on echocardiography or
CT, as well as myocardial injury as indicated by a positive
test for cTnI or troponin T.21 Compared with the 10% 30-day
mortality in our study cohort, short-term death occurred
infrequently in the trial’s placebo arm (3.2%). This ﬁnding
might support the requirement of clinical variables in
addition to cardiac biomarkers and imaging testing to
identify the sickest normotensive patients with acute symptomatic PE.
Practice guidelines suggest that most patients with intermediate-high risk PE should receive standard anticoagulation alone,4,22 and guideline-adherent management strongly
correlates with patient outcomes.23 In this study, only a small
proportion of patients received immediate thrombolytic
TH Open
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therapy. Since these patients had more severe hemodynamic
decompensation compared with those who received delayed
thrombolysis, future trials should evaluate the efﬁcacy and
safety of reperfusion therapies in intermediate-high risk
patients who have an overwhelming accumulation of prognostic factors indicative of a more marked cardiopulmonary
impairment.
Clinical practice guidelines suggest close monitoring of
patients with intermediate-high risk PE, and prompt treatment if decompensation occurs. However, it is not clear how
long these patients should be monitored, and the optimal
method to assess early response to anticoagulant therapy. In
the PEITHO trial, mean time from enrolment to deterioration
in the placebo arm was 1.8  1.6 days.21 For this reason, this
study assessed clinical variables, cardiac biomarkers, and
echocardiography within 48 hours after diagnosis of acute PE
to explore the optimal method to assess response to anticoagulant treatment. Our results suggest that resolution of
tachycardia might be a reliable tool to identify those patients
with a negligible risk of deterioration within the ﬁrst few
days. Compared with cardiac biomarker testing and echocardiography, measurement of HR is a simple, inexpensive,
rapid, repeatable, and easily interpretable tool for risk
assessment.
Our ﬁndings should be interpreted in the context of our
study design and its limitations. Despite the large number of
normotensive patients with acute PE assessed for this study,
the number of patients with intermediate-high risk PE did
not allow for more precision in our estimates. In the present
study, echocardiograms were done and interpreted by a
limited number of certiﬁed cardiologists and thus the results
cannot be necessarily applied to less experienced operators.
The study protocol did not collect information on clot location and degree of obstruction in a standardized fashion.
Thus, the study cannot report such information. Further, this
was a single-center study at a large referral center and
treatment-related decisions may not be necessarily reﬂective of all other centers.
In conclusion, in this cohort of consecutive patients with
acute PE, intermediate-high risk PE was found in 10% of
normotensive patients. Such patients had markedly worse
outcomes compared with other normotensive patients with
PE, suggesting the need for close monitoring. Assessment of
HR may be useful to estimate the response to anticoagulation
and the risk of deterioration.
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